alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 551–575 of 1,109 studies · tagged Digital Tools (page 23 of 45) · 27,380 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Amyloidogenic processing but not amyloid precursor protein (APP) intracellular C-terminal domain production requires a precisely oriented APP dimer assembled by transmembrane GXXXG motifs

✓ Peer-reviewed alzhub usefulness score 44 out of 100. The Journal of biological chemistry 2008-01-16

The beta-amyloid peptide (Abeta) is the major constituent of the amyloid core of senile plaques found in the brain of patients with Alzheimer disease. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Amyloid-beta deposition is associated with decreased hippocampal glucose metabolism and spatial memory impairment in APP/PS1 mice

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Journal of neuropathology and experimental neurology 2004-05-01

In Alzheimer disease (AD) patients, early memory dysfunction is associated with glucose hypometabolism and neuronal loss in the hippocampus. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

TREM2 overexpression rescues cognitive deficits in APP/PS1 transgenic mice by reducing neuroinflammation via the JAK/STAT/SOCS signaling pathway

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Experimental neurology 2020-10-13

Overactivated microglia and neuroinflammation are considered to play a crucial role in the progression of Alzheimer's disease (AD). 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Diagnostic accuracy of ELISA and xMAP technology for analysis of amyloid beta(42) and tau proteins

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Clinical chemistry 2007-03-29

Cerebrospinal fluid (CSF) concentrations of amyloid beta(42) (Abeta(42)) peptides and tau proteins may serve as biomarkers for Alzheimer disease (AD). 4 key findings →

Participants: 69 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Telehealth among Medicare Advantage beneficiaries with and without Alzheimer's Disease and Related Dementias (ADRD), 2018–2024: from pandemic-era surge to post-pandemic decline

✓ Peer-reviewed alzhub usefulness score 44 out of 100. BMC Health Services Research 2026-03-13

Among 421,131 MA beneficiaries, telehealth use increased sharply in Q2 2020 for both ADRD and non-ADRD groups, peaking at 33.9 and 30.6% respectively. 5 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Artificial intelligence in drug development for delirium and Alzheimer’s disease

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Acta Pharmaceutica Sinica B 2025-04-28

Delirium is a common cause and complication of hospitalization in the elderly and is associated with higher risk of future dementia and progression of existing dementia, of which 70% is Alzheimer's disease (AD). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

AI-Based Severity Classification of Dementia Using Gait Analysis

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Sensors 2025-10-02

This study aims to explore the utility of artificial intelligence (AI) in classifying dementia severity based on gait analysis data and to examine how machine learning (ML) can address the limitations of conventional statistical approaches. 1 key finding →

Participants: 34 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Combining EEG, event-related potentials, and MRI biomarkers for detection of mild cognitive impairment: A machine learning approach

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Clinical Neurophysiology 2026-05-06

EEG/ERP analysis suggested differences in frontal alpha asymmetry, power ratio, and ERP components between the MCI and CN groups. 5 key findings →

Participants: 70 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Key informants’ perceptions of telehealth palliative care for people living with dementia in nursing homes

✓ Peer-reviewed alzhub usefulness score 44 out of 100. BMC Geriatrics 2025-03-19

(n = 14) included NH administrators and other leaders, palliative care providers, telehealth representatives, dementia advocates, a care partner, and a PLWD. 5 key findings →

Participants: 14 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Expert opinion on Alzheimer's disease diagnostics and management in Central Eastern European countries representing 88 million population

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2026-09-09

The expert panel from Croatia, Czech Republic, Hungary, Poland, Romania, Slovakia and Slovenia discussed the current situation of various topics related to the diagnostics, general management and treatment of Alzheimer's disease (AD) in these Central Eastern European (CEE) countries, representing around 88 million population. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source

Computerized cognitive testing battery identifies mild cognitive impairment and mild dementia even in the presence of depressive symptoms

✓ Peer-reviewed alzhub usefulness score 44 out of 100. American journal of Alzheimer's disease and other dementias 2006-01-01

Cognitive and depressive symptoms co-occur, complicating detection of mild cognitive impairment (MCI) and early dementia. 5 key findings →

Participants: 72 Evidence: low

Full summary, score breakdown and related studies → Original source

Validity of the Mindstreams computerized cognitive battery for mild cognitive impairment

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Journal of molecular neuroscience : MN 2004-01-01

The NeuroTrax Mindstreams computerized cognitive assessment system was designed for widespread clinical and research use in detecting mild cognitive impairment (MCI). 1 key finding →

Participants: 30 Evidence: low

Full summary, score breakdown and related studies → Original source

The telehealth satisfaction scale: reliability, validity, and satisfaction with telehealth in a rural memory clinic population

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Telemedicine journal and e-health : the official journal of the American Telemedicine Association 2014-10-01

The study findings demonstrate high user satisfaction with telehealth in a rural memory clinic and the sound psychometric properties of the TeSS in this population. 2 key findings →

Participants: 223 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Unsupervised machine learning for the discovery of latent disease clusters and patient subgroups using electronic health records

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of biomedical informatics 2019-12-28

Machine learning has become ubiquitous and a key technology on mining electronic health records (EHRs) for facilitating clinical research and practice. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

User evaluation of the DEMentia-specific Digital Interactive Social Chart (DEM-DISC). A pilot study among informal carers on its impact, user friendliness and, usefulness

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Aging & mental health 2010-05-01

The positive effects might be caused by the systematic and tailored individual way of information provisioning by DEM-DISC. 1 key finding →

Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Advances in Deep Neuropathological Phenotyping of Alzheimer Disease: Past, Present, and Future

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of neuropathology and experimental neurology 2022-01-01

Alzheimer disease (AD) is a neurodegenerative disorder characterized pathologically by the presence of neurofibrillary tangles and amyloid beta (Aβ) plaques in the brain. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

From across this tag

8 of the 1,102 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 8. The same 8 appear here every time.

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed